RayKnowChina Research Map
Shortlist

Not yet recruitingLung cancerPhase 2

Registered title, quoted from ClinicalTrials.gov

Clinical Study of Ivonescimab Combined With Concurrent Chemoradiotherapy in the Treatment of Advanced Non-small Cell Lung Cancer

An open trial on lung cancer, registered on ClinicalTrials.gov. Led by Affiliated Cancer Hospital of Guizhou Medical University; 0 other hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Lead (inferred)Affiliated Cancer Hospital of Guizhou Medical University贵州医科大学附属肿瘤医院GuiyangHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT07936578, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 7

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (7 points)Hide the checklist
  1. 18 years to 75 years; sex: all

    Registered eligibility fields

  2. Previously untreated, histopathologically or cytologically confirmed unresectable PD-L1 TPS ≥ 1% Stage IV non-small cell lung cancer

    Inclusion criterion 3

  3. Childbearing age women must have a serum pregnancy test within 3 days before the first dose, and the result must be negative. Female subjects of childbearing age and male subjects with partners of childbearing age must agree to use highly effective methods of contraception during the study and for 180 days after the last dose of the study drug.

    Inclusion criterion 11

    Patients with a history of another malignancy within 5 years before the first dose, other than non-small cell lung cancer, are excluded. This exclusion does not apply to malignancies with a negligible risk of metastasis or death (e.g., expected disease-free survival >5 years) that are expected to achieve a curative outcome after treatment (e.g., adequately treated cervical carcinoma in situ, basal cell or squamous cell skin cancer, or ductal carcinoma in situ treated with curative-intent surgery).

    Exclusion criterion 11

  4. ECOG performance status score of 0-1

    Inclusion criterion 7

  5. Have measurable lesions according to Response Evaluation Criteria in Solid Tumors version 1.1

    Inclusion criterion 4

  6. Known human immunodeficiency virus (HIV) infection (known HIV antibody positive)

    Exclusion criterion 7

  7. Female subjects who are pregnant, breastfeeding, or planning to become pregnant during the study.

    Exclusion criterion 14

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; blood tests: counts, liver and kidney function.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07936578, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Have fully understood this study and voluntarily signed the Informed Consent Form (ICF)
  • Aged 18 to 75 years, regardless of gender
  • Previously untreated, histopathologically or cytologically confirmed unresectable PD-L1 TPS ≥ 1% Stage IV non-small cell lung cancer
  • Have measurable lesions according to Response Evaluation Criteria in Solid Tumors version 1.1
  • Have adequate pulmonary function tests (PFTs)
  • Subjects must be able to provide a prior driver gene report based on tissue or blood testing, and the test results must show that targetable driver genes such as EGFR sensitive mutations, ALK rearrangement or fusion, and ROS1 fusion are all negative; or if a certain type of driver gene is positive but the targeted drug is not available, the subject may be enrolled. If the subject does not have a driver gene test report, tumor samples (archived or fresh, primary or metastatic) or blood samples must be collected before enrollment for driver gene testing to confirm negativity (at a local laboratory or central laboratory)
  • ECOG performance status score of 0-1
  • Adequate organ and bone marrow function

① Hematology: Absolute neutrophil count (ANC) ≥ 1500/μL; Platelets ≥ 100,000/μL; Hemoglobin ≥ 9.0 g/dL or ≥ 5.6 mmol/L.

② Renal: Serum creatinine ≤ 1.5 × ULN or calculated creatinine clearance (CrCl) ≥ 60 mL/min (using the Cockcroft-Gault formula).

③ Hepar: Total bilirubin ≤ 1.5 × ULN, or for subjects with total bilirubin levels > 1.5 × ULN, direct bilirubin within normal limits; AST (SGOT) and ALT (SGPT) ≤ 2.5 × ULN.

④ Adequate coagulation function: International Normalized Ratio (INR) and Activated Partial Thromboplastin Time (APTT) ≤ 1.5 × ULN; Known left ventricular ejection fraction (LVEF) ≥ 50%; Urine protein < 1+ or if urine protein is 1+, further 24-hour urine protein quantification < 1.0 g.

  • Endocrine System: Thyroid-stimulating hormone (TSH) within normal limits. Note: If TSH is not within the normal range at baseline, the subject may still meet the inclusion criteria if T3 and free T4 are within the normal range;Coagulation function: International Normalized Ratio (INR) or Prothrombin Time (PT), Activated Partial Thromboplastin Time (APTT) ≤ 1.5 × ULN, except for subjects receiving anticoagulant therapy, as long as PT or aPTT is within the intended therapeutic range of the anticoagulant drug.
  • Willing and able to comply with the study plan's visits, treatment plans, laboratory tests, and other study procedures.
  • Childbearing age women must have a serum pregnancy test within 3 days before the first dose, and the result must be negative. Female subjects of childbearing age and male subjects with partners of childbearing age must agree to use highly effective methods of contraception during the study and for 180 days after the last dose of the study drug.

Exclusion Criteria:

  • Presence of resectable or metastatic disease
  • History of interstitial lung disease, drug-induced interstitial lung disease, or radiation pneumonitis requiring steroid therapy, or currently receiving drug treatment or other clinical interventions, or presence of active pulmonary interstitial lesions or imaging findings of interstitial lung disease.
  • Known history of active tuberculosis
  • Known active infection requiring systemic therapy
  • Any known or suspected autoimmune disease or immunodeficiency, except for: patients with a history of hypothyroidism who do not require hormone therapy or are receiving physiological doses of hormone replacement therapy; patients with stable blood glucose-controlled type 1 diabetes.
  • Uncontrolled active hepatitis B (defined as positive hepatitis B surface antigen [HBsAg] test at screening with HBV-DNA levels above the upper limit of normal of the study center's laboratory; patients with HBV-DNA <500 IU/mL within 28 days before enrollment who have received at least 14 days of standard local antiviral therapy and are willing to continue antiviral therapy during the study may be enrolled); active hepatitis C (defined as positive hepatitis C virus surface antibody [HCsAb] test at screening with positive HCV-RNA).
  • Known human immunodeficiency virus (HIV) infection (known HIV antibody positive)
  • Vaccination with live vaccines within 30 days before the first dose, including but not limited to: mumps, rubella, measles, varicella/zoster (chickenpox), yellow fever, rabies, BCG, and typhoid vaccine (inactivated virus vaccines are allowed).
  • History of severe allergic reactions to other monoclonal antibodies;
  • Known severe or uncontrolled underlying diseases
  • Patients with a history of another malignancy within 5 years before the first dose, other than non-small cell lung cancer, are excluded. This exclusion does not apply to malignancies with a negligible risk of metastasis or death (e.g., expected disease-free survival >5 years) that are expected to achieve a curative outcome after treatment (e.g., adequately treated cervical carcinoma in situ, basal cell or squamous cell skin cancer, or ductal carcinoma in situ treated with curative-intent surgery).
  • Class III-IV congestive heart failure (New York Heart Association classification), poorly controlled and clinically significant arrhythmias.
  • Any arterial thrombosis, embolism, or ischemia within 6 months before enrollment, such as myocardial infarction, unstable angina, cerebrovascular accident, or transient ischemic attack.
  • Female subjects who are pregnant, breastfeeding, or planning to become pregnant during the study.
  • Investigators consider other conditions that may make the patient unsuitable for participation in this clinical trial.

Quoted from ClinicalTrials.gov, NCT07936578, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT07936578, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT07936578